September 11, 2024 by Diabetologia Credit: Pixabay/CC0 Public DomainThe anti-obesity medication semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with overweight or obesity who don’t have diabetes, whether or not they also have impaired kidney function, according to new research to be...
September 3, 2024 by Perelman School of Medicine at the University of Pennsylvania Credit: Unsplash/CC0 Public DomainTaking the weight loss medication semaglutide did not increase the risk of depressive symptoms, suicidal thoughts, or suicidal behavior in persons without known major mental health disorders, according to a new study led by researchers from the Perelman School...
Medscape Diabetes & EndocrinologyCOMMENTARY Kevin Fernando, MBChB, MSc Diabetes, BSc DISCLOSURES | June 03, 2024 There has been much hyperbole since the presentation of results from the SELECT cardiovascular outcomes trial (CVOT) at this year’s European Congress on Obesity, which led many to herald semaglutide as the “new statin.” In the SELECT CVOT, participants with...
August 3, 2024 by Elana Gotkine Semaglutide products are being sold online, with products likely unregistered or unlicensed, according to a research letter published online Aug. 2 in JAMA Network Open. Amir Reza Ashraf, Pharm.D., from the University of Pécs in Hungary, and colleagues conducted a risk assessment of semaglutide online sourcing. Websites advertising semaglutide...
Written by Sophie Vergnaud, MD | Reviewed by Alyssa Billingsley, PharmDUpdated on July 8, 2024 Key takeaways: New research has shown a link between taking semaglutide (Ozempic, Wegovy) and a rare kind of eye stroke called non-arteritic anterior ischemic optic neuropathy (NAION) — especially in the first year of taking the medication. Semaglutide has also...
JULY 3, 2024 by D’Or Institute for Research and Education Credit: CC0 Public DomainA study published in the Journal of Clinical Anesthesia investigated the relationship between semaglutide use and residual gastric content in patients undergoing upper gastrointestinal endoscopy (EGD). Conducted by researchers at the D’Or Institute for Research and Education (IDOR), the retrospective study analyzed...
JUNE 3, 2024 by Case Western Reserve University Credit: Pixabay/CC0 Public DomainA new study by researchers at the Case Western Reserve University School of Medicine reveals that the popular diabetes and weight-loss drugs Wegovy and Ozempic are linked to reduced incidence and recurrence of alcohol abuse or dependence. The team’s findings, recently published in the...
by Elana Gotkine For patients with type 2 diabetes mellitus, most eyes have no worsening of diabetic retinopathy (DR) after initiation of semaglutide, according to a study presented at the annual meeting of the American Academy of Ophthalmology, held from Nov. 3 to 6 in San Francisco. Zeeshan Haq, M.D., from Retina Consultants of Minnesota...
Marlene Busko October 31, 2023 With nutrient-stimulated hormone therapies for obesity in phase 3 trials, and activin-receptor inhibitors the next upcoming drug class, highly effective treatments for obesity are on the horizon. “We are at a watershed [moment] brought on by the recent introduction of highly effective antiobesity medications,” said Ania M. Jastreboff, MD, PhD, in a...
Katherine Lewin | News Reporter Novo Nordisk’s GLP-1 Wegovy has shown cardiovascular benefit again, this time in the Phase III STEP HFpEF trial, on top of the expected weight loss, the company announced at the European Society of Cardiology (ESC) Congress today. Against placebo, 2.4 mg of Wegovy (semaglutide) showed “large” reductions in heart failure-related...
